
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
This customer note will demonstrate the suitability of SEC for a fast and reproducible evaluation of adeno-associated virus (AAV) product titers







